Flixotide 125micrograms / dose Evohaler (GlaxoSmithKline UK Ltd) 120 dose

Type Pressurised aerosol inhaler (MDI)
Medicine Fluticasone 125micrograms/dose
Adult steroid dose Medium adult steroid dose
Activation mechanism Non breath actuated
Dose counter No dose counter
Price £21.26 / 30 days
(based on 4 puffs / day)
Inhaled corticosteroid information For children and adults, a total of 4 puffs/day gives a medium dose of ICS
Steroid safety card recommendation (for adults) Steroid safety card recommended
Licences
  • Adult Asthma Licence
  • Adolescent Asthma Licence age range not available
  • Paediatric Asthma Licence age range not available

Spacers

There are 50 compatible spacers

Training material

Pathways

The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Asthma - prophylaxis

Type Age Range Dose Licensed
Maintenance From 16 years 1 actuation - TWICE a DAY - inhalation
Maintenance From 16 years 2 actuations - TWICE a DAY - inhalation
Maintenance From 16 years 3 actuations - TWICE a DAY - inhalation
Maintenance From 16 years 4 actuations - TWICE a DAY - inhalation

Drug Interactions

With Risk Severity
RITONAVIR Increased risk of systemic corticosteroid adverse effects High Risk: Avoid combination. Risk outweighs benefits.
(ATAZANAVIR WITH COBICISTAT) Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(INDINAVIR) Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(NELFINAVIR) Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(SAQUINAVIR) Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(TELITHROMYCIN) Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
CLARITHROMYCIN Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
COBICISTAT Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DARUNAVIR WITH COBICISTAT Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR DISOPROXIL Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
IDELALISIB Increased risk of systemic corticosteroid adverse effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.